SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurogen (NRGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (203)2/4/1999 11:51:00 AM
From: HB  Read Replies (2) of 523
 
Are you suggesting that 95-2 might have proved effective in clinical
trials against chronic anxiety, despite its failure in situational
anxiety trials?
Is this phenomenon seen in the existing literature, or with approved
drugs? Are further clinical trials in the cards?

As you can see, I am not an expert on the science here, but I have
done well trading Neurogen over time-frames of months to a year, by
buying when they announce disappointments, relying on the breadth of
their pipeline,
and waiting for the gradual move up which always seems to come.
(By sheer luck, I traded out of a shorter-term position a few
days before this announcement!)
But the fact that they keep
coming up with these buying opportunities bothers me.

HB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News